GLA and Fabry disease: Intravenous enzyme replacement therapy (ERT) with agalsidase beta (Fabrazyme®) is approved for patients with Fabry disease aged ≥2 years in the United States of America (USA) and ≥8 years in Europe (28, 29), and ERT with agalsidase alfa (Replagal®) is approved for use in patients with Fabry disease, with dosage recommendations for ages 7–65 years (30).